By Sabela Ojea
Predictive Oncology has signed a deal to be taken over by Renovaro in exchange for a newly created series of preferred stock in the biotechnology company.
The AI-driven drug-discovery company on Monday said that the acquisition, which follows a formal review of strategic alternatives put in place since mid-November, would reduce its operating expenses by more than 30% on a combined basis in the near term.
The acquisition is subject to a minimum fundraising of $15 million by Renovaro, as well as formal approval by Predictive Oncology's shareholders.
There is no assurance that an agreement or transaction with Renovaro will be executed.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 06, 2025 09:22 ET (14:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。